Hospices Civils de Lyon (HCL) - Hôpital des Charpennes
- Address
- lock Available on a paid plan
Neurology & Cognitive Disorders
At Hospices Civils de Lyon – Hôpital des Charpennes, investigators are advancing therapies for neurodegenerative conditions. Current trials focus on Alzheimer’s disease and mild cognitive impairment, assessing safety and efficacy through the Clinical Dementia Rating‑Sum of Boxes.
- Biomarker-driven early Alzheimer’s interventions
- Intrathecal delivery of therapeutic agents
- Cognitive outcome assessment using CDR‑SB
- Safety monitoring in mild dementia cohorts
The program involves four investigators and five active studies, reflecting a strong commitment to improving outcomes for patients with early and mild dementia.
Movement Disorders Research
Research at the centre includes a detailed examination of Parkinson’s disease. The primary goal is to compare the expression of the serotonergic 5‑HT4 receptor between patients and age‑matched healthy volunteers, providing insights that could guide future therapeutic strategies.
- Serotonergic 5‑HT4 receptor expression profiling
- Comparative analysis with age‑matched controls
- Exploration of neural pathways in Parkinson’s
- Foundations for receptor‑targeted drug development
These investigations are part of the broader effort in musculoskeletal and neural physiological phenomena, linking receptor biology to movement disorder pathology.
Neuropsychiatry & Behavioral Health
A key focus is the management of agitation associated with Alzheimer’s disease. Trials are testing a new combination therapy to reduce behavioral symptoms, measured by the Cohen‑Mansfield Agitation Inventory. The investigational agent KarXT is being evaluated for its potential to improve patient calmness and safety.
- Behavioral symptom measurement (CMAI‑IPA)
- Combination therapy efficacy evaluation
- Safety and tolerability in elderly dementia patients
- Impact on caregiver burden and patient quality of life
This neuropsychiatric work aligns with the site’s expertise in mental disorders and aims to enhance quality of life for individuals living with dementia.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Biogen Idec Research Limited1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospices Civils de Lyon (HCL) - Hôpital des Charpennes
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia | Biogen Idec Research Limited | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (1-(111C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXYLATE | 1 | Unknown | 2023-09-18 | 2023-09-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.